Aortic Aneurysm Stent Grafts - Market Insights, Competitive Landscape, and Market Forecast - 2030

Aortic Aneurysm Stent Grafts Devices Market by Product (Abdominal Aortic Stent Graft and Thoracic Aortic Stent Graft), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing prevalence of lifestyle disorders and the rising product developmental activities worldwide

The aortic aneurysm stent grafts devices market is growing at a CAGR of 5.71% during the forecast period from 2024 to 2030. The aortic aneurysm stent grafts devices market is observing substantial market growth primarily owing to the increasing prevalence of lifestyle disorders including diabetes, the rising geriatric population, innovative product developmental activities by regulatory bodies, and the rising adoption of minimally invasive procedures that are expected to escalate the overall growth of the aortic aneurysm stent grafts devices market during the forecast period from 2024 to 2030.

Aortic Aneurysm Stent Grafts Devices Market Dynamics:

According to data from the International Diabetes Federation (2022), in 2021, 537 million adults aged 20-79 were living with diabetes, equating to about 1 in 10 individuals. This number is expected to increase to 643 million by 2030 and reach 783 million by 2045. Notably, over 75% of adults with diabetes reside in low- and middle-income countries. Additionally, 541 million adults have impaired glucose tolerance, putting them at elevated risk for developing type 2 diabetes. Diabetes-related hypertension, atherosclerosis, and obesity elevate aneurysm risks, necessitating increased use of stent grafts for minimally invasive aneurysm management in this high-risk group, there is a growing demand for aortic aneurysm stent grafts devices.

Increased product developmental activities by the regulatory bodies worldwide are also slated to witness market growth for aortic aneurysm stent graft devices. For example, in June 2023, Cook Medical received FDA approval to initiate an investigational device exemption (IDE) study for an aortic aneurysm treatment. The study will evaluate the Zenith Fenestrated+ Endovascular Graft (ZFEN+).

Therefore, all the factors stated above collectively will drive the overall aortic aneurysm stent grafts devices market growth.

However, complications associated with aortic aneurysm stent grafts devices, and others may prove to be challenging factors for the aortic aneurysm stent grafts devices market growth.

Aortic Aneurysm Stent Grafts Devices Market Segment Analysis:

Aortic Aneurysm Stent Grafts Devices Market by Product (Abdominal Aortic Stent Graft and Thoracic Aortic Stent Graft), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of aortic aneurysm stent graft devices, the abdominal aortic stent graft category is expected to have a significant revenue share in the year 2023. This is because of the widespread uses and various key features of abdominal aortic stent grafts that enhance their utility and effectiveness.

Abdominal aortic stent grafts are endovascular devices designed specifically for the treatment of abdominal aortic aneurysms, facilitating aneurysm repair without open surgery. Constructed from biocompatible, durable materials like nitinol or stainless steel for the stent frame and woven polyester or polytetrafluoroethylene. These devices provide structural integrity and promote vascular remodeling. Key features include self-expanding or balloon-expandable designs, advanced anchoring mechanisms to prevent migration, and fenestrations or branches for cases involving complex aneurysms near renal or iliac arteries.

These have achieved widespread clinical adoption, particularly in cases where patients present with comorbidities or are considered at high-risk for open surgery. The success of abdominal aortic stent grafts in reducing aneurysm-related mortality also have spurred continued development in device customization, addressing variable aortic anatomies and improving patient outcomes through tailored endovascular solutions.

Additionally, in August 2024, Terumo India, announced the launch of the TREO Stent-Graft System, an advanced solution for Endovascular Aneurysm Repair (EVAR). Designed specifically for the treatment of infrarenal abdominal aortic aneurysms in adults with suitable anatomies, the TREO(R) Stent-Graft System stands out as the only EVAR graft featuring both suprarenal and infrarenal active fixation.

Therefore, the widespread uses and various key features of abdominal aortic stent graft that enhance performance and usability coupled with introduction of new and innovative products are solidifying the impact on the growth of the overall abdominal aortic stent graft devices market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall aortic aneurysm stent grafts devices market:

Among all the regions, North America is expected to dominate the aortic aneurysm stent grafts devices market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high instances of diabetes, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure are acting as key factors contributing to the growth of the aortic aneurysm stent grafts devices market in the North America region during the forecast period from 2024 to 2030.

As per the recent data provided by the Centre for Disease Control and Prevention (2024), in 2021, 38.4 million people of all ages, or 11.6% of the US population had diabetes. The rising diabetic population is expanding demand for aortic aneurysm stent grafts, as diabetes heightens vascular complications, weakening the aortic wall. Diabetic patients' higher surgical risk makes minimally invasive stent grafts a preferred intervention, driving market growth in aneurysm management.

Product developmental activities initiated by regulatory bodies and key manufacturers will further boost the market for aortic aneurysm stent grafts devices. For example, in May 2021, Endologix LLC, a leader in the treatment of vascular disease, announced the first implant of its ALTO(R) Abdominal Stent Graft in Canada following recent approval from Health Canada.

Additionally, in August 2021, Terumo Aortic announced that the US Food and Drug Administration (FDA) granted approval of its RelayPro thoracic stent-graft system for sale in the USA for the treatment of patients with thoracic aortic aneurysms (TAA) and penetrating atherosclerotic ulcers (PAUs).

The prompt and well-established healthcare services and infrastructure further contribute to the growth of the regional aortic aneurysm stent grafts devices market growth. The presence of key players such as Cook, Medtronic, and Cordis, with their strong distribution networks, ensure widespread availability and accessibility of these devices across the region increasing their revenue shares in the market, and supportive reimbursement programs providing immense growth opportunities for the same.

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American aortic aneurysm stent grafts devices market.

Aortic Aneurysm Stent Grafts Devices Market key players:

Some of the key market players operating in the aortic aneurysm stent graft devices market include Medtronic, Terumo Corporation, Microport Scientific Corporation, Cook, Cordis, W. L. Gore & Associates, Inc., Endologix LLC, SB-KAWASUMI LABORATORIES, INC., Endospan, Lombard Medical, and others.

Recent Developmental Activities in the Aortic Aneurysm Stent Grafts Devices Market:

• In June 2024, Medtronic launched the Steerant Aortic Guidewire, tailored to facilitate catheter placement and exchange during diagnostic or interventional procedures in the aorta.
• In January 2023, Medtronic announced the first patient enrollment in the ADVANCE Trial, a head-to-head randomized controlled trial of two leading aortic stent graft systems, the Endurant II/IIs stent graft system, and GORE Excluder AAA Device Family systems.
• In September 2022, Getinge joined forces with Medtronic to launch Radiant stent for ChEVAR procedures in Europe. The first covered stent indicated for chimney endovascular aneurysm repair (ChEVAR). This new balloon-expandable stent graft for renal arteries obtained CE mark approval in September 2022.

Key Takeaways from the Aortic Aneurysm Stent Grafts Devices Market Report Study

• Market size analysis for current aortic aneurysm stent grafts devices market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the aortic aneurysm stent grafts devices market.
• Various opportunities available for the other competitors in the aortic aneurysm stent grafts devices market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current aortic aneurysm stent grafts devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for aortic aneurysm stent grafts devices market growth in the coming future?

Target Audience who can be benefited from this Aortic Aneurysm Stent Grafts Devices Market Report Study

• Aortic aneurysm stent grafts device product providers
• Research organizations and consulting companies
• Aortic aneurysm stent grafts devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in aortic aneurysm stent grafts devices
• Various end-users who want to know more about the aortic aneurysm stent grafts devices market and the latest technological developments in the aortic aneurysm stent grafts devices market

Frequently Asked Questions for the Aortic Aneurysm Stent Grafts Devices Market:

1. What are aortic aneurysm stent grafts devices?

• The aortic aneurysm stent grafts are devices placed inside the abdominal aorta or thoracic aorta to help protect the aneurysm from rupturing. The stent graft is placed inside the aneurysm with the help of a long, very thin, soft, plastic tube called a delivery catheter.

2. What is the market for aortic aneurysm stent grafts devices?

• The aortic aneurysm stent grafts devices market is growing at a CAGR of 5.71% during the forecast period from 2024 to 2030.

3. What are the drivers for the aortic aneurysm stent grafts devices market?

• The aortic aneurysm stent grafts devices market is observing substantial market growth primarily owing to the increasing prevalence of lifestyle disorders including diabetes, the rising geriatric population, innovative product developmental activities by the regulatory bodies, and the rising adoption of minimally invasive procedures that are expected to escalate the overall growth of the aortic aneurysm stent grafts devices market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the aortic aneurysm stent grafts devices market?

• Some of the key market players operating in aortic aneurysm stent grafts devices include Medtronic, Terumo Corporation, Microport Scientific Corporation, Cook, Cordis, W. L. Gore & Associates, Inc., Endologix LLC, SB-KAWASUMI LABORATORIES, INC., Endospan, Lombard Medical, and others.

5. Which region has the highest share in the aortic aneurysm stent grafts devices market?

• North America is expected to dominate the overall Aortic Aneurysm Stent Grafts Devices market during the forecast period from 2024 to 2030. This can be attributed to several factors including the high instances of diabetes, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure are acting as key factors contributing to the growth of the aortic aneurysm stent grafts devices market in the North America region during the forecast period from 2024 to 2030.